Company news

Nektar Therapeutics news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

December 11, 2022

Nektar Therapeutics to Host Investor & Analyst Event on December 12th

December 4, 2022

Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 9, 2022

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy

November 8, 2022

Nektar Therapeutics Reports Third Quarter 2022 Financial Results

November 2, 2022

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets

October 24, 2022

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress

September 6, 2022

Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma

August 15, 2022

Nektar Therapeutics Reports Second Quarter 2022 Financial Results

August 3, 2022

Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets

July 25, 2022

Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer

June 30, 2022

Nektar Therapeutics Reports First Quarter 2022 Financial Results

May 4, 2022

Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook

April 24, 2022

Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

April 22, 2022

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan

April 21, 2022

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)

April 13, 2022

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial

March 13, 2022

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

March 13, 2022

Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results

February 27, 2022

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets

February 16, 2022

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

January 4, 2022

Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis

December 14, 2021

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting

November 29, 2021

Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

November 14, 2021

Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 11, 2021

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 8, 2021

Nektar Therapeutics Reports Third Quarter 2021 Financial Results

November 3, 2021

Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets

October 25, 2021

Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study

September 20, 2021

Nektar Therapeutics Reports Second Quarter 2021 Financial Results

August 4, 2021

Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets

July 26, 2021

Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

July 18, 2021

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

June 6, 2021

Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity

May 19, 2021

Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)

May 17, 2021

Nektar Therapeutics Reports First Quarter 2021 Financial Results

May 5, 2021

Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets

April 26, 2021

Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results

February 24, 2021

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets

February 17, 2021

Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer

February 16, 2021

Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)

February 16, 2021

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

January 5, 2021

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development

January 4, 2021

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

December 21, 2020

Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer

December 14, 2020

Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting

December 6, 2020

Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 10, 2020

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

November 8, 2020

Nektar Therapeutics Reports Third Quarter 2020 Financial Results

November 4, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.